Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
13:59
In Moscow, gas stations impose limits on fuel sales, despite the authorities' efforts to ensure supply.
13:54
The second Ukrainian suspect in the Nord Stream explosions case from 2022, arrested in Croatia
13:46
New leadership at the State Agency for Intellectual Property of Moldova. Natalia Mogol replaces Iulian Iorga.
13:43
Russia and Ukraine have carried out a new prisoner exchange, with each side handing over 103 soldiers.
13:26
Fines of over 130,000 lei, issued by ANSVSA after inspections at units selling food in gas stations
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
